anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a porcine epidemic diarrhea S1 protein fusion gene, recombinant bacillus megaterium strain and application. An antigen fusion gene shown as SEQ ID No. 1. is obtained by connecting an antigen locus of porcine epidemic diarrhea virus (PEDV) S glycoprotein and a cell wall anchoring sequence. The invention further constructs a secretion expression vector containing the antigen fusion gene, and secretion expression vector is converted into the bacillus megaterium to express recombinant protein on the cell wall or surface of the bacillus megaterium. Immunoblotting experiments indicate that the expressed recombinant protein can react with PEDV immune serum and has the same antigenicity as PEDV natural antigens. Immunofluorescent tests of live bacteria which are subjected to induced expression indicate that the expressed recombinant protein is positioned to the surfaces of the bacteria. Experiment results indicate that the recombinant protein can be prepared into safe and effective mucous immune live vaccines for preventing and treating porcine epidemic diarrhea.
The present invention is a method of a non-continuous administration of a pharmaceutical to a female for a condition associated with the female's menstrual cycle, compromising in the administration of either 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone, (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid or RS)-2-(4-(2-methylpropyl) phenyl) propanoic acid. The active ingredients to be manufactured into a tablet or chewable formulation rich in cocoa flavonols such as dark chocolate no more than 65%. A method of inhibiting one or more symptom of premenstrual syndrome/late luteal phase dysphoric disorder compromising of administering to a female in need of treatment an effective amount of a compound. The first dose to be given at the onset of the premenstrual symptoms. This can be given two to four times a day up to seven days as directed. This is intended to be a short course of therapy to alleviate the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder.
The present invention relates to a Chinese herbal medicine product which is capable of stopping drug addiction within three days and eliminating withdrawal syndrome. The present invention is prepared from the following Chinese herbal medicine: 30g of ephedra, 60g of rhizoma corydalis, 15g of ginseng, 30g of rhizoma gastrodiae, 45g of eucommia bark, 30g of grosvenor momordica fruits, 90g of Chinese dates, 15g of licorice roots, 30g of hawthorns, 60g of honey and 45g of rhubarb. The present invention can be prepared into oral liquid, syrup, tablets, capsules, tea, pills, etc. and solves the problem that poison is used for stopping drug addiction in common traditional medicine for stopping drug addiction. Therefore, traditional therapies, such as a diminishing method, a substitution method, a sleep method, etc. are eliminated, and the purpose that drug addicts can thoroughly stop drug addiction within three days can be achieved. The present invention has the characteristics of no pain, low expense, short time, etc. and solves the problem of high relapse rate.
Participants will be randomly allocated to either the ECT or MST group. Each center aims to recruit 30 participants for each group, using block randomization, resulting in a total of 30 participants per group. The trial comprises a 12-session intervention phase of ECT/MST, spanning approximately 4 weeks, followed by a 12-week observation period. For the first three treatment sessions, participants will receive consecutive sessions. Subsequently, there will be a one-day interval between sessions 4 to 6, a two-day interval between sessions 7 to 9, and a three-day interval between sessions 10 to 12, ensuring completion within a month. Following treatment completion, participants will undergo follow-up clinical observations every four weeks for 12 weeks. EEG and ECG recordings will be obtained at baseline, post-session 3, 6, 9, 12 (3 hours after each session), and at the 12-week follow-up. All evaluations will be conducted under standardized conditions throughout the sessions.
The invention belongs to the technical field of medicines, relates to a preparation method of an aqueous extract in a compound preparation, and concretely relates to a preparation method of the aqueous extract in an anti-colorectal cancer compound preparation Amorphophallus konjac and Iphigenia indica granule. The method is characterized in that the content of polysaccharides is determined through establishing a phenol-sulfuric acid technology, and water extraction of Amorphophallus konjac and Iphigenia indica particles is carried out by adopting an L9(3<4>) orthogonal experiment design with the polysaccharide extraction rate as an index. Experiment parameters for determination of the polysaccharide content through the phenol-sulfuric acid technology are determined through the method, and are characterized in that the addition amount of a phenol solution is 0.8ml, the addition amount of concentrated sulfuric acid is 5.0ml, and the boiling water bath heating color development time is 5min. Extraction is carried out by using 20 times water for 1.5h twice, and the polysaccharide extraction rate stably reaches 14.4%. In the preparation process of the aqueous extract, the boiling time, the water addition amount and the extraction frequency are controlled to effectively control an experiment error and obtain a stable extraction effect. The extraction method is simple, feasible, stable and reliable.
FIELD: cosmetics. SUBSTANCE: composition is in nonaqueous form based on silicon oil, containing homogeneous fat phase formed from 5-97 wt.% of only silicon oil and 3-50 wt.% of fat phase, wax with melting temperature 50-135 C and formed at least one polymer with mas.wt. 200-1500, separated from homopolymers and copolymers of ethylene with monomer. Composition may be used as a means for makeup, fluid powder and lipstick. EFFECT: high stability and softness. 12 cl, 4 expa
Objective: Analyze the effects of Nordic Walking and free walking in the clinical-functional parameters, postural balance, muscular echography quality, pendulum gait mechanism, in people with Multiple sclerosis. Experimental Design: Randomized controlled multicenter clinical trial with translational study characteristics. Search Location: Exercise Research Laboratory at the School of Physical Education, Physiotherapy and Dance, Federal University of Rio Grande do Sul, Brazil, and University of Pavia, on Department of Public Health, Experimental Medicine and Forensic Sciences, Pavia, Italy. Participants: 60 patients from the Unified Health System (UHS) of both sexes, from 20 to 75 years old, diagnosed with multiple sclerosis, sedentary. Interventions: In this research, four groups of patients with multiple sclerosis will receive intervention during 4 months of different physical therapy programs (Nordic walking and free walking), who will receive telephone guidance for performing home-based exercises. The training programs will have a duration of 3 months and will be periodized so that the duration of the sessions is matched between them. The intensity of the interval training will be manipulated by the subjective effort scale (Borg) and by the heart rate, with predetermined series durations. All training programs will have a frequency of two sessions per week and a duration of 60 minutes. To evaluate the effects of the training, evaluations will be performed before and after the training period: 1) Basal (month 0): initial pre-training evaluation; 2) month 4: Evaluation 48h after the last training session. Outcomes: clinical-functional parameters, postural balance, muscular echography quality, pendulum gait mechanism, and biochemistry. Data Analysis: Data will be described by average values and standard deviation values. The comparisons between and within groups will be performed using a Generalized Estimating Equations (GEE) analysis, adopting a level of significance (α) of 0.05. Expected Results: The intervention groups of the Nordic walking are expected to be more effective in all outcomes analyzed, especially improving functional mobility when compared to the control group of unsupervised home exercises. In addition, it is expected that the results of the research will be expandable and the possibility of future developments in the scientific, technological, economic, social, and environmental fields and that they will be implemented in the Unified Health System (UHS).
Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
PURPOSE:To provide a new compound having an anti-inflammatory effect, an antipyretic and analgesic effect and an antiarthritic effect, reduced in toxicity and useful as an anti-inflammatory drug, especially a therapeutic agent for arthritis. CONSTITUTION:A compound is represented by formula I [Y is N or CG (G is carboxyl); Ring R is a nitrogen-containing unsaturated heterocycle; (n) is 1 to 4; (k) is 0 to 1] or its salt, e.g. 6,7-dimethoxy-4-(3,4-dimethoxyphenyl)-2-(2- ethylimidazol-1-ylmethyl)quinoline-3-carboxylic acid ethyl ester. This compound is synthesized by reacting a compound of formula II (Q is an eliminable group) or its salt with a compound of formula III or its salt in the presence of a base such as sodium hydride in a solvent such as DMF preferably at -10 to 100 deg.C. In addition, the raw material compound of formula II is obtained, e.g. by reacting a 2-aminobenzophenone derivative of formula IV with a compound of the formula QCH2COCH2G' (G' is an esterified carboxyl) in the presence of an acid such as sulfuric acid.
250 patients with locally advanced or metastatic gastric carcinoma or carcinoma of the esophagogastric junction without prior palliative therapy will be treated with 8 cycles of the FLOT scheme (up to 12 cycles if the response is favourable). Prior to enrolment a unique and detailed clinical evaluation of the dissemination of the disease will be done which includes a differentiated regard of the M-category in the TNM classification. A prospective stratification will classify the patients as having either (A) locally advanced, (B) limited metastatic, or (C) extensive metastatic disease. In addition, the pharmacogenetic risk profile of the patients will be evaluated by a combined analysis of two genetic polymorphisms of the metabolism of the applied substances (XPD312, GSTT1). For the assessment of the disease, reference regions are examined by CT or MRI scans and if applicable endoscopy prior to the start of the study, every 2 months during and after the end of therapy until progression of the disease occurs. Evaluation of quality of life (by standard forms like EORTC-Q30 and others) is continued after progression. Clinical examinations (blood count, assessment of toxicity, anamnesis) is performed every two weeks for evaluation of toxicity and application of chemotherapy. After informed consent is given, peripheral blood of the patient will be analysed for the pharmacogenetic risk profile. Representative tumor material will be analysed by immunohistochemistry and quantitative PCR for the expression of several molecular factors.
Safety and effectiveness in pediatric patients 12 years of age and older have been established based on pharmacokinetic data in adults and adolescents using levetiracetam extended-release tablets and efficacy and safety data in controlled pediatric studies using immediate-release levetiracetam tablets [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)].

Safety and effectiveness in pediatric patients below the age of 12 have not been established.

A 3-month, randomized, double-blind, placebo-controlled study was performed to assess the neurocognitive and behavioral effects of immediate-release levetiracetam tablets as adjunctive therapy in 98 pediatric patients with inadequately controlled partial seizures, ages 4 to 16 years (levetiracetam N = 64; placebo N = 34). The target dose of immediate-release levetiracetam tablets was 60 mg/kg/day. Neurocognitive effects were measured by the Leiter-R Attention and Memory (AM) Battery, which assesses various aspects of a child's memory and attention. Although no substantive differences were observed between the placebo- and levetiracetam-treated groups in the median change from baseline in this battery, the study was not adequate to assess formal statistical non-inferiority between the drug and placebo. The Achenbach Child Behavior Checklist (CBCL/6-18), a standardized validated tool used to assess a child’s competencies and behavioral/emotional problems, was also assessed in this study. An analysis of the CBCL/6-18 indicated a worsening in aggressive behavior, one of the eight syndrome scores, in patients treated with levetiracetam [see Warnings and Precautions (5.1)].

Juvenile Animal Toxicity Data   
Studies of levetiracetam in juvenile rats (dosed on postnatal days 4 through 52) and dogs (dosed from postnatal weeks 3 through 7) at doses of up to 1,800 mg/kg/day (approximately 7 and 24 times, respectively, the maximum recommended pediatric dose of 60 mg/kg/day on a mg/m2 basis) did not demonstrate adverse effects on postnatal development.
Dysmenorrhea is a kind of visceral pain that result of peritoneal irritation. It is so common in gynecological outpatient practice. Most of treatment is based pharmacological treatments as NSAIDs, oral contraceptives with many side effects. Kinesio taping is widely used for musculoskeletal parenchymal pain like sports related injuries. As in other complementary treatment methods like acupuncture and acupressure; pain carrying unmyelinated thin pain fibers are blocked by touch sensation carrying myelinated thick fibers which is stimulated by acupressure(gate control theory by Melzack), kinesio taping blocks the pain fibers that comes from same spinal level. So it can be used easily and instantly for dismenore
A method for manufacturing oriental material extracts from houttuynia cordata thunb is provided to recover a function of a liver damaged by LPS and prevent a liver cell from being damaged by LPS. A method for manufacturing oriental material extracts from houttuynia cordata thunb comprises the following steps of: preparing a mixture by mixing 90wt.pt. of houttuynia cordata thunb with 1-3wt.pt. of Schizandrae Fructus, 1-3wt.pt. of Lycii Fructus, 3-5wt.pt. of Torilidis Fructus, and 1-3wt.pt. of Epimedii Herba; adding 1900-2100wt.pt. of distilled water to the mixture, reflux-cooling the mixture, and filtering the mixture to obtain an extract; and reducing pressure to concentrate the extract.
PURPOSE: To cross-culturally adapt and validate the Radboud Dysarthria Assessment (RDA) and the speech component of the Radboud Oral Motor inventory for Parkinson's disease (ROMP-speech) into the Arabic language among Lebanese subjects with dysarthria.
MATERIALS AND METHODS: This study included 50 participants with dysarthria. The Arabic versions of the RDA (A-RDA) and the ROMP-speech (A-ROMP-speech) were administered in addition to the Arabic Speech Intelligibility test, the Lebanese Voice Handicap Index-10 (VHI-10lb) and semantic verbal fluency tasks. The maximum performance tasks were analyzed using the Praat software. The A-RDA qualitative recording form and the A-ROMP-speech were assessed for construct validity and internal consistency. The convergent validity of the maximum performance tasks, the severity scale, and the A-ROMP-speech were evaluated.
RESULTS: Exploratory factor analysis of the qualitative recording form extracted 3 factors explaining 82.973% of the total variance, and it demonstrated high internal consistency (α = 0.912). The maximum performance tasks of the RDA correlated significantly with the corresponding Praat scores. The severity scale and the A-ROMP-speech correlated fairly to strongly with the Arabic Speech Intelligibility test (rs=-0.695 and -0.736, p < 0.001) and the VHI-10lb (r = 0.539 and 0.640, p < 0.001).
CONCLUSION: The A-RDA and the A-ROMP-speech are valid and reliable dysarthria tools among Lebanese subjects.
Premature infants with respiratory distress syndrome (RDS) usually require respiratory support . Due to the complications of intubation and mechanical ventilation, in the last decade, attempts have been made to use non-invasive methods in the management of these patients . Over the past few decades, nasal ventilation has been used to control and improve respiratory failure in infants with RDS . nCPAP is a relatively simple and effective therapy in the early management of RDS in newborns . nCPAP is the application of positive pressure to the airways of spontaneously breathing neonates throughout the respiratory cycle . However, some neonates with this therapeutic approach also develop respiratory failure and need mechanical ventilatory support. According to some investigations, 43%-80% of infants with moderate to severe respiratory failure who are initially treated with nCPAP need mechanical ventilation .

In recent years, the beneficial effects of high-frequency ventilators (HFV) have been shown in the management of RDS as well as the use of this mode as the initial mode of support or as a rescue treatment after failure of conventional mechanical ventilation. In high-frequency ventilation, a low tidal volume with a higher frequency than that of physiological respiration is produced. This technique is very effective in eliminating carbon dioxide (CO2). Adequate recruitment of lung volume in this mechanical mode has the main role of protecting and preserving lung architecture as well as potentiating surfactant therapy.

The nHFOV is a non-invasive ventilation mode that applies an oscillatory pressure waveform to the airways using a nasal interface. nHFOV is effective and superior to nasal intermittent positive pressure ventilation in terms of lung CO2 elimination. This mode has been shown to facilitate CO2 elimination, but little is known about its use in neonates. There is increasing evidence of beneficial effects of nHFOV in reducing the duration of ventilator support compared with the effects of nCPAP in RDS. We intended to explore the benefits of nHFOV vs nCPAP in preterm neonates.
* Stop levonorgestrel and ethinyl estradiol if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.
  * Stop levonorgestrel and ethinyl estradiol if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.
  * If feasible, stop levonorgestrel and ethinyl estradiol at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.
  * Start levonorgestrel and ethinyl estradiol no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.
  * The use of COCs increases the risk of VTE. However, pregnancy increases the risk of VTE as much or more than the use of COCs. The risk of VTE in women using COCs is 3 to 9 cases per 10,000 woman- years. The risk of VTE is highest during the first year of use of COCs and when restarting hormonal contraception after a break of 4 weeks or longer. The risk of thromboembolic disease due to COCs gradually disappears after use is discontinued.
  * Use of levonorgestrel and ethinyl estradiol provides women with more hormonal exposure on a yearly basis than conventional monthly COCs containing the same strength synthetic estrogens and progestins (an additional 9 weeks of exposure per year). In the clinical trial, one case of pulmonary embolism was reported. Postmarketing adverse reactions of VTE have been reported in women who used levonorgestrel and ethinyl estradiol.
  * Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. Stroke has been reported in women associated with the use of levonorgestrel and ethinyl estradiol. COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes). This risk increases with age, particularly in women over 35 years of age who smoke.
  * Use COCs with caution in women with cardiovascular disease risk factors.
PURPOSE:To prepare a water-in-oil type emulsion with good stability, by compounding an appropriate amount of a specific sorbitan fatty acid ester, a soap and another nonionic surfactant as an emulsifier composition. CONSTITUTION:As an emulsifier composition, 100pts.wt. sorbitan fatty acid ester having flowability at 0 deg.C such as sorbitan ester or sorbitol ester, 1.5- 20pts.wt. soap and 5-50pts.wt. other surfactant such as polyoxyethylene alkylphenyl ether or polyoxyethylene alkyl ether are compounded. The obtained emulsifier composition is used in preparing a water-in-oil type emulsion with extremely good stability.
BACKGROUND: Heart disease and chronic kidney disease are often comorbid conditions owing to shared risk factors, including diabetes and hypertension. However, the effect of congestive heart failure (CHF) on arteriovenous fistula (AVF) and AV graft (AVG) patency rates is poorly understood. We hypothesize preexisting HF may diminish blood flow to the developing AVF and worsen patency.
METHODS: We conducted a single-institution retrospective review of 412 patients with end-stage renal disease who underwent hemodialysis access creation from 2015 to 2021. Patients were stratified based on presence of preexisting CHF, defined as clinical symptoms plus evidence of reduced left ventricular ejection fraction (EF) (<50%) or diastolic dysfunction on preoperative echocardiography. Baseline demographics, preoperative measures of cardiac function, and dialysis access-related surgical history were collected. Kaplan-Meier time-to-event analyses were performed for primary patency, primary-assisted patency, and secondary patency using standard definitions for patency from the literature. We assessed differences in patency for patients with CHF vs patients without CHF, patients with a reduced vs a normal EF, and AVG vs AVF in patients with CHF.
RESULTS: We included 204 patients (50%) with preexisting CHF with confirmatory echocardiography. Patients with CHF were more likely to be male and have comorbidities including, diabetes, chronic obstructive pulmonary disease, hypertension, and a history of cerebrovascular accident. The groups were not significantly different in terms of prior fistula history (P = .99), body mass index (P = .74), or type of hemodialysis access created (P = .54). There was no statistically significant difference in primary patency, primary-assisted patency, or secondary patency over time in the CHF vs non-CHF group (log-rank P > .05 for all three patency measures). When stratified by preoperative left ventricular EF, patients with an EF of <50% had lower primary (38% vs 51% at 1 year), primary-assisted (76% vs 82% at 1 year), and secondary patency (86% vs 93% at 1 year) rates than those with a normal EF. Difference reached significance for secondary patency only (log-rank P = .029). AVG patency was compared against AVF patency within the CHF subgroup, with significantly lower primary-assisted (39% vs 87% at 1 year) and secondary (62% vs 95%) patency rates for AVG (P < .0001 for both).
CONCLUSIONS: In this 7-year experience of hemodialysis access creation, reduced EF is associated with lower secondary patency. Preoperative CHF (including HF with reduced EF and HF with preserved EF together) is not associated with significant differences in overall hemodialysis access patency rates over time, but patients with CHF who receive AVG have markedly worse patency than those who receive AVF. For patients with end-stage renal disease and CHF, the risks and benefits must be carefully weighed, particularly for those with low EF or lack of a suitable vein for fistula creation.